Market Closed -
Toronto S.E.
12:41:25 2024-07-08 pm EDT
|
5-day change
|
1st Jan Change
|
0.05
CAD
|
-16.67%
|
|
-28.57%
|
-33.33%
|
Fiscal Period: November |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4.588
|
4.917
|
2.855
|
9.164
|
8.025
|
5.308
|
Enterprise Value (EV)
1 |
4.621
|
4.98
|
3.197
|
8.387
|
8.013
|
5.343
|
P/E ratio
|
-7.27
x
|
-7.81
x
|
-2.48
x
|
-4.15
x
|
-4.3
x
|
-3.73
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-9,388,412
x
|
-3,246,873
x
|
-4,253,009
x
|
-5,021,081
x
|
-4,375,693
x
|
EV / FCF
|
-9.01
x
|
-8.35
x
|
-58.1
x
|
-7.96
x
|
-6.73
x
|
-9.15
x
|
FCF Yield
|
-11.1%
|
-12%
|
-1.72%
|
-12.6%
|
-14.8%
|
-10.9%
|
Price to Book
|
8.9
x
|
6.52
x
|
9.32
x
|
4.81
x
|
5.52
x
|
3.7
x
|
Nbr of stocks (in thousands)
|
53,975
|
65,563
|
71,366
|
101,820
|
114,638
|
132,702
|
Reference price
2 |
0.0850
|
0.0750
|
0.0400
|
0.0900
|
0.0700
|
0.0400
|
Announcement Date
|
4/5/19
|
4/3/20
|
3/30/21
|
3/17/22
|
3/30/23
|
3/26/24
|
Fiscal Period: November |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-0.5305
|
-0.9846
|
-1.972
|
-1.596
|
-1.221
|
EBIT
1 |
-0.8458
|
-0.5326
|
-1.138
|
-1.974
|
-1.605
|
-1.223
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-0.5559
|
-0.5523
|
-1.139
|
-2.051
|
-1.754
|
-1.399
|
Net income
1 |
-0.5559
|
-0.5523
|
-1.139
|
-2.051
|
-1.754
|
-1.399
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0117
|
-0.009598
|
-0.0162
|
-0.0217
|
-0.0163
|
-0.0107
|
Free Cash Flow
1 |
-0.5126
|
-0.5962
|
-0.0551
|
-1.054
|
-1.19
|
-0.5838
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/5/19
|
4/3/20
|
3/30/21
|
3/17/22
|
3/30/23
|
3/26/24
|
Fiscal Period: November |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.03
|
0.06
|
0.34
|
-
|
-
|
0.03
|
Net Cash position
1 |
-
|
-
|
-
|
0.78
|
0.01
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.1188
x
|
-0.3475
x
|
-
|
-
|
-0.0282
x
|
Free Cash Flow
1 |
-0.51
|
-0.6
|
-0.06
|
-1.05
|
-1.19
|
-0.58
|
ROE (net income / shareholders' equity)
|
-261%
|
-87%
|
-215%
|
-185%
|
-104%
|
-96.5%
|
ROA (Net income/ Total Assets)
|
-49.5%
|
-23.2%
|
-49.4%
|
-64.2%
|
-43%
|
-35.9%
|
Assets
1 |
1.123
|
2.384
|
2.308
|
3.194
|
4.076
|
3.898
|
Book Value Per Share
2 |
0.0100
|
0.0100
|
0
|
0.0200
|
0.0100
|
0.0100
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0.0100
|
0
|
0
|
Capex
1 |
0.33
|
0.18
|
0.16
|
0.43
|
0.28
|
0.17
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/5/19
|
4/3/20
|
3/30/21
|
3/17/22
|
3/30/23
|
3/26/24
|
|
1st Jan change
|
Capi.
|
---|
| -33.33% | 6.14M | | +57.48% | 823B | | -7.18% | 353B | | +15.37% | 320B | | +7.45% | 295B | | +13.62% | 239B | | +14.55% | 220B | | -0.33% | 219B | | +8.14% | 167B | | -2.99% | 159B |
Other Pharmaceuticals
|